SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹12 Cr | ₹10.00 Cr | ₹8.66 Cr | ₹7.76 Cr | ₹7.73 Cr |
What is the latest Total Non-Current Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹12 Cr |
| Mar2024 | ₹10.00 Cr |
| Mar2023 | ₹8.66 Cr |
| Mar2022 | ₹7.76 Cr |
| Mar2017 | ₹7.73 Cr |
How is Total Non-Current Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹12 Cr | 18.16 | |
| Mar2024 | ₹10.00 Cr | 15.49 | |
| Mar2023 | ₹8.66 Cr | 11.53 | |
| Mar2022 | ₹7.76 Cr | 0.36 | |
| Mar2017 | ₹7.73 Cr | - | |
Compare Total Non-Current Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,233.3 Cr | -3.2% | 7.5% | -25.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹413,753.0 Cr | 1.5% | 5.5% | 0.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,032.0 Cr | 2.3% | 3.6% | 7.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹143,426.0 Cr | -0.5% | 5.3% | 40.2% | Stock Analytics | |
| CIPLA | ₹108,360.0 Cr | -1.1% | -2.2% | -8.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,859.0 Cr | 0.9% | 5.2% | 7% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | -3.2% |
7.5% |
-25.4% |
| SENSEX | 0.2% |
1.1% |
8.8% |
You may also like the below Video Courses